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Role of GLUT1 gene in susceptibility to diabetic nephropathy saturated at or near physiologic glucose concentrations
in type 2 diabetes. [6–8]. The SGLT1 transporter of mesangial cells is also a
Background. The XbaI polymorphism in the glucose trans- high-affinity transporter that similarly could be saturatedporter GLUT1 gene has been implicated in the development
under normal glucose conditions [9, 10]. This suggests,of diabetic nephropathy in Chinese type 2 diabetes patients.
as postulated by Heilig, Brosius and Henry, that in orderMethods. To examine whether the XbaI polymorphism is
involved in the development of diabetic nephropathy in Cauca- for mesangial cells to take up excessive quantities of
sian type 2 diabetes patients, a large case control study was glucose in diabetes, changes in glucose transporter ex-
performed. The study group of 444 patients with type 2 diabetes pression, translocation, or activity may be required [3].
consisted of three subgroups: 162 patients with normoalbumi-
Several studies observed a regulatory role of the mesan-nuria (only patients with duration of type 2 diabetes of at least
gial cell GLUT1 activity in glucose metabolism and ex-10 years after diagnosis); 150 with microalbuminuria; and 132
subjects with persistent proteinuria or chronic renal failure tracellular matrix synthesis [1, 11].
(CRF). The polymerase chain reaction (PCR)-based genotyp- Because only a subset of patients with type 1 and type
ing of the XbaI polymorphism was performed in each subject. 2 diabetes is susceptible to develop diabetic nephropa-
Results. The genotype distribution in the subgroups showed
thy, it was postulated that there might be a differencean increased frequency of the (1/1) genotype in patients with
in the activity of GLUT1 between those who are suscep-microalbuminuria (41%; OR 1.40, 95% CI, 0.89 to 2.24) and
proteinuria/CRF (47%; OR 1.82, 95% CI, 1.13 to 2.93, P 5 tible and those who are not. This difference may be
0.013) when compared with normoalbuminuria (33%). No dif- caused by a protein variant or by a polymorphism in the
ference in the genotype distribution was observed between regulatory part of the gene involved in the expression. A
type 2 diabetes patients and healthy controls.
common XbaI restriction fragment length polymorphismConclusions. The results of this study in Caucasian patients
(RFLP) has been identified in the GLUT1 gene [12],with type 2 diabetes indicate that the XbaI(2) allele in the
GLUT1 gene protects against the development of diabetic and Fukumoto et al [13] located it in the second intron
nephropathy. Our results are in contrast to the case control approximately 4.5 kbp upstream of exon 3. Several stud-
study in Chinese patients with type 2 diabetes in which the ies investigated the role of the XbaI RFLP in the suscep-
presence of the XbaI(2) allele appeared to have a strong
tibility to type 2 diabetes, but the results were inconclu-association with the development of diabetic nephropathy.
sive. Li et al reported an association between type 2
diabetes and the XbaI polymorphism of the GLUT1
gene in Japanese subjects [14]. The study of Tao et alSeveral glucose transporters have been identified in
confirmed the association of the XbaI(2) allele withglomeruli [1–5]. These include the facilitative glucose
type 2 diabetes in Japanese population [15]. Baroni ettransporter isoforms GLUT1, GLUT3, and GLUT4, and
al suggested an association between polymorphic mark-sodium-glucose cotransporter SGLT1 [1–5]. GLUT1,
ers at the GLUT1 locus and type 2 diabetes in the ItalianGLUT3, and GLUT4 are all high-affinity, low-capacity,
population, but this effect could not be confirmed in thefacilitative glucose transporters that typically would be
following studies [16–19].
There were few studies searching for the association
between the diabetes-related complications and the XbaIKey words: glucose transporter, NIDDM, XbaI polymorphism, chronic
renal failure, hyperglycemia, microalbuminuria, proteinuria. polymorphism in the GLUT1 gene. Gutierrez et al evalu-
ated the role of the XbaI polymorphism in the suscepti-Received for publication January 28, 2000
bility to microvascular complications in type 2 diabetesand in revised form August 15, 2000
Accepted for publication August 18, 2000 [20]. There were no differences in genotypic or allelic
distribution among patients for either the presence orÓ 2001 by the International Society of Nephrology
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absence of retinopathy or nephropathy [20]. In a recent criteria and were genotyped for the XbaI polymorphism.
For six subjects, the genotype was not assessed becausegenetic study in Chinese type 2 diabetic patients, how-
ever, the XbaI(2) allele conferred a significantly higher of technical problems. In the analyzed study group of 444
subjects, 132 patients had overt proteinuria, includingsusceptibility to diabetic kidney disease [21]. In that case
control study, the frequency of the XbaI genotype was 46 patients with chronic renal failure (CRF; defined as
persistent rise in serum creatinine $1.5 mg/dL; 16 pa-compared between patients with diabetic nephropathy
(urinary albumin excretion .200 mg/min) and without tients were dialyzed), and 150 had ACR in the range of
microalbuminuria; these patients were considered the[21]. The frequency of the XbaI(2) allele carriers in
patients with diabetic nephropathy was higher than in two groups of cases. One hundred sixty-two patients had
normoalbuminuria, with known diabetes duration $10patients without renal complication [21].
To examine whether the XbaI polymorphism is in- years, thus representing a group of control subjects. The
evaluation of patients also included eye examinationvolved in the susceptibility to diabetic nephropathy in
Caucasian patients with type 2 diabetes, we performed (fundus camera examination, with retinopathy status
graded by two independent observers as nihil, simplex,a large case control study and compared the frequency
of the XbaI genotype in the subgroups of patients with preproliferative or proliferative, with fluorescein angiog-
raphy and third evaluation performed in case of discrep-and without renal complications.
ancies). From the total number of 450 patients included
in the three groups, retinal status was available for 391
METHODS
patients (59 patients either did not attend eye examina-
Selection of study patients tion or retinal status was difficult to obtain, mostly be-
cause of bilateral cataract or others). Patients were con-Between January 1, 1998, and December 31, 1998,
each patient with type 2 diabetes (diagnosed according sidered hypertensive if they were on antihypertensive
medication or if systolic or diastolic BP taken at time ofto the National Diabetes Data Group criteria [22]) at-
tending the Outpatient Clinic for Diabetic Patients in microalbuminuria screening and during subsequent visit
in the clinic was $140 or 90 mm Hg (blood pressure wasZabrze and willing to participate in the study was
screened for microalbuminuria in a random urine sample measured twice with a mercurium sphygmomanometer,
in the supine position, after at least 10 min of rest, and theusing the semiquantitative dipstick MICRAL II test
(Boehringer Mannheim, Mannheim, Germany). Patients results were averaged). Two hundred forty-three patients
were taking antihypertensive treatment, and among those,(N 5 1270) were screened for microalbuminuria, and all
dipstick-positive ($20 mg albumin/dL) as well as dip- 162 were taking angiotensin-converting enzyme inhibi-
tors. Glycemic control at the time before the examinationstick-negative patients with a known diabetes duration
of at least 10 years were ascertained for verification of was assessed by measuring glycated HbA1c blood levels
on an HPLC Variant System (Bio-Rad, Hercules, CA,renal status by means of repeated measurements of albu-
min/creatinine ratio (ACR) in random urine samples, USA).
We collected and genotyped 194 healthy subjects fromserum creatinine concentration, and careful review of
medical files. Albumin concentration in urine was mea- the population of the same region in southern Poland
to assess the frequency of genotypes.sured by immunoturbidometric assay on a TurbiTimer
with the Albumin-Urine kits (Dade Behring, Leider- All enrolled patients were Caucasians and gave writ-
ten informed consent for participation in the study. Thebach, Germany). Serum and urine creatinine concentra-
tions were measured by spectrophotometry on a Kodak study protocol was approved by the Ethics Committee
of Silesian School of Medicine.automated system. Normoalbuminuria was defined as an
ACR (mg/mmol) of less than 1.9 for men and less than
Genetic markers and genotyping2.8 for women [23]. Overt proteinuria was defined as an
ACR greater than or equal to 28.2 for men and greater To test the previously reported association with dia-
betic nephropathy [21], we genotyped the XbaI polymor-than or equal to 40.2 for women. Microalbuminuria was
defined as an ACR in the range between normoalbumin- phism in the GLUT1 gene [12] in all 444 type 2 diabetes
patients and 194 healthy controls. Genotyping for theuria and overt proteinuria. Albuminuria and proteinuria
were diagnosed on the basis of the consensus of two out XbaI polymorphism was performed by polymerase chain
reaction (PCR)-based protocols using the previously re-of three determinations (the interval between the mea-
surements was at least 2 weeks) and no data suggesting ported primer sequences [15] and restriction of the PCR
product with the XbaI enzyme. The PCR product afternondiabetic kidney disease in medical files (mostly acute
or chronic urinary tract infection, asymmetrical kidney digestion was resolved electrophoretically on the agarose
gel. Consistently with the first report of Tao et al, thesize, a rise in serum creatinine level after ACE inhibition,
rapid decline of renal function or systemic symptoms of 1.1 kb undigested allele was called (2), and the allele
that gave the restriction site for XbaI and was observedvasculitis). Altogether, 450 patients met the selection
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Table 1. Clinical characteristics of type 2 diabetes patients used in the study according to nephropathy status (means 6 SD)
Normoalbuminuria Microalbuminuria Proteinuria or CRF Healthy controls
N 163 155 132 194
Gender male/female 53/110 82/73 61/71 89/105
Age at examination years 64.367.8a 62.068.2a 62.068.9 44.067.8
Age at diagnosis of NIDDM years 48.569.4 49.7612.3 50.8610.3 —
Known NIDDM duration years 15.865.5c 11.266.8c 11.267.0c —
Body mass index kg/m2 29.364.5 29.964.3 29.064.3 27.064.2
HbA1c % 8.961.7 9.261.7b 8.461.8b —
Hypertension % 51.8b 62.8a 79.6a,b —
Retinopathy %
Any 54.2 49.7 61.6 —
Background 49.7 41.4 40.7 —
Preproliferative/proliferative 4.5 8.3 20.9 —
Abbreviations are: CRF, chronic renal failure; NIDDM, non-insulin dependent diabetes.
a P , 0.05
b P , 0.01
c P , 0.001
after digestion as two fragments 0.9 and 0.2 kb was called Table 2 shows the distribution of XbaI genotypes in
(1) [15]. the three study subgroups. The population of healthy
controls was not distorted from the Hardy–Weinberg
Statistical analysis equilibrium. In the normoalbuminuria group, the excess
All statistical analyses were made with STATISTICA of XbaI(2/1) heterozygotes caused a distortion from
for Windows version 5.0. Quantitative variables were the Hardy–Weinberg equilibrium (x2 5 5.54, P 5 0.02,
tested by analysis of variance, and frequencies were 1 degree of freedom) that was also mirrored in the whole
tested by chi-square test. The odds ratio (OR) was calcu- group of patients with type 2 diabetes (x2 5 4.71, P 5
lated, and a 95% confidence interval (95% CI) was pro- 0.03, 1 degree of freedom). Comparing the frequency of
vided. Because the normoalbuminuria group contained genotypes among the analyzed subgroups, we found that
patients with the duration of type 2 diabetes after diagno- the frequency of genotypes in patients with proteinuria/
sis of at least 10 years, the assumptions for analysis of CRF was different from patients with normoalbuminuria
variance were not met, and a nonparametric Man-Whit- (x2 5 6.3, 2 degrees of freedom, P 5 0.04). When the
ney test was used. patients with microalbuminuria were compared with
The Hardy–Weinberg equilibrium was examined by normoalbuminuria group, there was no difference in the
the goodness-of-fit chi-square test with the continuity genotype distribution. When microalbuminuria and pro-
correction [24]. teinuria/CRF were combined together and compared
A multivariate logistic regression was performed, in- with normoalbuminuria, a borderline significance was
cluding into model XbaI genotype, gender, systolic blood observed (x2 5 5.2, 2 degrees of freedom, P 5 0.07).
pressure, and HbA1c. There was no significant difference in the genotype distri-
bution between the healthy subjects from Polish popula-
tion and the patients with type 2 diabetes.RESULTS
In Table 3, the frequency of the XbaI(1/1) genotypeThe study patients with normoalbuminuria, microal-
was compared among the groups. The XbaI(2/2) andbuminuria, and proteinuria/CRF did not differ with re-
(2/1) genotypes were grouped together assuming thegard to age at diagnosis of type 2 diabetes or body mass
autosomal/recessive model. The XbaI(2/2) genotype isindex (Table 1). Patients with normoalbuminuria had
relatively rare, and grouping it together with the XbaIlonger known duration of type 2 diabetes after diagnosis
(2/1) genotype allowed us to reduce the degrees of free-than subjects with microalbuminuria and proteinuria/
dom in the analysis. There was a higher frequency ofCRF, but they were collected with the assumption that
XbaI(1/1) genotype in the group with proteinuria/CRFthe duration of type 2 diabetes after diagnosis should be
than in normoalbuminuric patients with the OR 1.82at least 10 years to avoid misclassifications. As presented
(95% CI, 1.13 to 2.93). Also, the frequency of XbaI(1/1)in Table 1, hypertension was more frequent in patients
genotype was higher in microalbuminuric patients than inwith microalbuminuria and proteinuria/CRF than in sub-
normoalbuminuria; however, the significance was reachedgroup with normoalbuminuria. Retinopathy, especially
only when two nephropathy groups (microalbuminuriathe preproliferative and proliferative types, also was
and proteinuria/CRF) were combined together (OR 1.59;more frequently diagnosed in patients with proteinuria/
CRF than in normoalbuminuria and microalbuminuria. 95% CI, 1.06 to 2.38). The frequency of XbaI(1/1) geno-
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Table 2. Distribution of XbaI genotypes in the study groups
XbaI(2/2) XbaI(2/1) XbaI(1/1)
Genotype N (%) x2 P
Normoalbuminuria 17 (10) 92 (57) 53 (33) (reference)
Microalbuminuria 15 (10) 74 (49) 61 (41) 2.2 0.33a
Proteinuria/CRF 12 (9) 58 (44) 62 (47) 6.3 0.04a
Nephropathy (microalbuminuria 1 proteinuria/CRF) 27 (9) 132 (47) 123 (44) 5.2 0.07a
Healthy Controls 28 (14) 82 (42) 84 (43)
Type 2 diabetes (normoalbuminuria 1 microalbuminuria 1 proteinuria/CRF) 44 (10) 224 (50) 176 (40) 4.7 0.1b
a When compared vs. normoalbuminuria (2 d.f.)
b When compared type 2 diabetes vs. healthy controls (2 d.f.)
Table 3. Comparison of the frequency of the XbaI(1/1) genotype among the study groups
XbaI(2/2) or (2/1) XbaI(1/1)
Genotype N (%) OR (95% CI)
Normoalbuminuria 109 (67) 53 (33) (reference)
Microalbuminuria 89 (59) 61 (41) 1.40 (0.89–2.24)
Proteinuria/CRF 70 (53) 62 (47)a 1.82 (1.13–2.93)
Nephropathy (microalbuminuria 1 proteinuria/CRF) 159 (56) 123 (44)b 1.59 (1.06–2.38)
Healthy controls 110 (57) 84 (43)
Type 2 diabetes (normoalbuminuria 1 microalbuminuria 1 proteinuria/CRF) 268 (60) 176 (40)c 0.85 (0.85–1.21)
a P 5 0.013 when compared proteinuria vs. normoalbuminuria (1 d.f.)
b P 5 0.024 when compared nephropathy vs. normoalbuminuria (1 d.f.)
c P 5 0.43 when compared type 2 diabetes vs. healthy controls (1 d.f.)
Table 4. Multiple logistic regression analysis for diabetic der, systolic blood pressure, and HbA1c (OR 5 1.67, 95%nephropathy (microalbuminuria 1 proteinuria/CRF)
CI, 1.08 to 2.57, P 5 0.021).
Odds There was no association between diabetic retinopa-
Risk Factor Unit Ratio 95% CI P value thy and the Xba(1/1) genotype. The genotype fre-
XbaI genotype (1/1)a 1.67 1.08–2.57 0.021 quency did not differ among those without or with sim-
Gender (male) 2.33 1.52–3.59 0.001
plex, preproliferative, or proliferative retinopathy. TheSystolic
blood pressure 10 mmHg 1.18 1.07–1.31 0.005 results were also negative when the study group was
HbA1c 1% 1.05 0.93–1.18 NS stratified by the renal status (data not shown).
In addition to the XbaI(1/1) genotype, gender, body mass index, and HbA1c
were entered into the model.
a The presence of the XbaI(1/1) genotype vs. XbaI(2/1) and XbaI(2/2) DISCUSSIONgenotypes grouped together
Our study showed that the XbaI(1/1) genotype was
more frequent in patients with diabetic nephropathy
than without this complication. This may indicate that
type did not differ between the population of type 2 the XbaI polymorphism in the intron 2 of the GLUT1
diabetes patients and 194 healthy controls from the pop- gene is responsible for the susceptibility to diabetic ne-
ulation of southern Poland. phropathy, or it is in linkage disequilibrium with a
Table 4 shows the multiple logistic regression analysis marker involved in the susceptibility. To our knowledge,
for diabetic nephropathy. In addition to the XbaI(1/1) this study is the first to show the positive association
genotype, other variables like gender, systolic blood between the XbaI polymorphism of the GLUT1 gene
pressure, and HbA1c were entered into the model. We and diabetic nephropathy in Caucasian patients with type
decided to exclude the duration of diabetes and age from 2 diabetes. A recently published study has shown a sig-
the model because the duration of diabetes was used as nificant distortion in the frequency of XbaI genotype
one of the selection criteria for the patients with nor- between groups with and without diabetic nephropathy
moalbuminuria to avoid misclassification, and patients in Chinese type 2 patients [21]. Our results are in contrast
with normoalbuminuria are older by the nature of the to the observation in Chinese population [21]. In the
disorder. As presented in Table 4, the presence of the present study, the XbaI(1/1) genotype was more fre-
XbaI(1/1) genotype was a risk factor for the develop- quent in patients with proteinuria/CRF than in normoal-
buminuria, but in the Chinese type 2 patients with ne-ment of diabetic nephropathy, when accounted for gen-
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phropathy, the XbaI(1/2) genotype was more frequent protects against nephropathy rather than the XbaI(1/1)
genotype predisposes to this complication.[21]. The XbaI(2/2) genotype was rare, and the fre-
quencies of the XbaI(1) and XbaI(2) alleles differed GLUT1 is the major representative of the family of
facilitative glucose transporters present in mesangialbetween healthy controls in Chinese and Polish popula-
tion (x2 5 12.04, 1 degree of freedom, P 5 0.0002). The cells [5]. As postulated by Heilig et al, glucose transport
activity, together with an increased intracellular glucoseassociation of opposite genotype with the same disease
in two different populations may be explained by several metabolism, is an important modulator of extracellular
matrix formation by mesangial cells [1]. It has beenscenarios. First, the results may be spurious in one of
those studies. In our study, the number of subjects with shown that factors potentially involved in the pathogene-
sis of diabetic nephropathy, such as transforming growthtype 2 diabetes (444) who were genotyped and analyzed
was roughly three times greater than in the study per- factor-b, stimulate glucose uptake by enhancing the ex-
pression of GLUT1 in mesangial cells. This leads to theformed in Chinese type 2 diabetes population (N 5 131)
[21], thus making our study less prone to be spurious. acceleration of intracellular metabolic abnormalities and
to the excessive production of extracellular matrix pro-Second, a different pattern of linkage disequilibrium may
be present in Caucasian than in Chinese population. The teins seen in diabetes [25]. Also, hyperglycemia itself
induces the GLUT1 expression, which can directly leadXbaI polymorphism is located in the intron 2, so it does
not cause a change of the protein sequence. The XbaI to the pathological changes of diabetic nephropathy [11].
As postulated by Mogyoro´si and Ziyadeh, it is thepolymorphism may be involved in a different expression
of GLUT1 itself; however, if this is the case, we would increased rate of glucose metabolism intracellularly that
promotes the pathological changes in diabetic nephropa-not observe an opposite result in Caucasian and Chinese
patients. A more probable situation would be that the thy [26]. From this perspective, it is clear that the activity
of glucose transporters on the cell surface of target cellsXbaI alleles are in linkage disequilibrium with another
disease marker, and the pattern of linkage disequilibrium may be a rate-limiting factor in the development of dia-
betic changes in the kidney [27]. Cell culture studies haveis different in Chinese and Caucasian populations. The
whole coding part of the GLUT1 gene has been analyzed shown that genetic overexpression of GLUT1 in rat mes-
angial cells can lead to the diabetic phenotype even in theby several groups, and only a few rare silent mutations
without functional significance have been found [15]. absence of high surrounding glucose level [1].
There were some differences in the collection of pa-Therefore, it is very unlikely that a common mutation
might be missed in the coding part of the gene that is tients and the criteria of nephropathy; however, it was
not very probable that it might be the main explanationin linkage disequilibrium with the XbaI polymorphism.
There might be a polymorphism in the regulatory part of the opposite observation in our study than in Chinese
type 2 diabetes patients. In our study, the frequency ofof the gene, which changes the expression of the gene
in the diabetic state. At present, there is no information the XbaI(1/1) genotype increased with each stage of
diabetic nephropathy. Patients with microalbuminuria hadabout the expression of GLUT1 in humans with diabetes
or diabetic nephropathy. A study is needed that will a higher frequency of XbaI(1/1) genotype than with nor-
moalbuminuria and in the group with proteinuria/CRFinvestigate the expression of GLUT1 in vivo depending
on the XbaI genotype. the frequency of XbaI(1/1) genotype was the highest.
Antihypertensive medication may reduce the albuminAnother possibility is a different genetic background
of both populations and different etiology of type 2 dia- excretion rate in type 2 diabetes patients, and this may
cause some misclassification of the renal status, whichbetes. An interesting observation was that the frequen-
cies of the XbaI alleles differed between healthy controls may decrease the power of the analysis. We analyzed the
genotype distribution after stratifying the patients by theand type 2 diabetes patients in Chinese population, and
they were almost identical when the type 2 diabetes antihypertensive medication, and the results were similar
to those in the whole study population (data not shown).patients were compared with healthy controls in Polish
population. Gutierrez et al did not observe any differences in geno-
typic or allelic distribution among patients for eitherThe frequency of the XbaI(1/1) genotype in patients
with nephropathy did not differ from healthy controls, presence or absence of retinopathy or nephropathy [20].
That study was performed in a Caucasian Mediterraneanbut the frequency of XbaI(1/1) genotype in patients
with normoalbuminuria was lower than in healthy sub- population, and only 193 type 2 diabetes patients were
analyzed. More than twice as many type 2 diabetes pa-jects. This might indicate that using stricter selection
criteria allowed us to detect the observed association. In tients were included into our study to gain more statistical
power to detect the association between diabetic nephrop-the normoalbuminuria group, we included only those
patients who had normoalbuminuria despite at least 10 athy and the XbaI polymorphism. This may explain why
the positive association observed by us was not foundyears of known diabetes duration. On the basis of this
observation, we should state that the XbaI(2) allele previously in the study of Gutierrez et al [20].
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transporter gene (GLUT) is on chromosome 1p31.3-p35. DiabetesIn conclusion, the results of this study in Caucasian
36:546–549, 1987
patients with type 2 diabetes indicate that the XbaI(2) 13. Fukumoto H, Seino S, Imura H, et al: Characterization and expres-
sion of human HepG2/erythrocyte glucose-transporter gene. Dia-allele in the GLUT1 gene protects against the develop-
betes 37:657–661, 1988ment of diabetic nephropathy. Our results are in contrast
14. Li SR, Baroni MG, Oelbaum RS, et al: Association of genetic
to the case control study in Chinese patients with type variant of the glucose transporter with non-insulin-dependent dia-
betes mellitus. Lancet 2:368–370, 19882 diabetes in which the presence of the XbaI(2) allele
15. Tao T, Tanizawa Y, Matsutani A, et al: HepG2/erythrocyte trans-appeared to have a strong association with the develop- porter (GLUT1) gene in NIDDM: A population association study
ment of diabetic nephropathy. and molecular scanning in Japanese subjects. Diabetologia 38:942–
947, 1995
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